Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing precision therapies for forms of sensorineural hearing loss. The firm's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The firm is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.

Industry: Pharmaceutical Preparations Peers: Acumen Pharmaceuticals Inc Armata Pharmaceuticals Inc Ardelyx Inc CHIMERIX INC LENZ Therapeutics Inc Oyster Point Pharma, Inc. ARS Pharmaceuticals Inc Verastem Inc